Contraline
PrivateLast Round
Series B
Jun 2, 2026
Est. Valuation
$53.5M
Total Funding Raised
$114.22M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Contraline operates in Healthcare & Life Sciences and is based in Charlottesville, Virginia. Its latest recorded funding round was a Series B round in June 2026.
Contraline is a biotechnology company developing a long-lasting, non-hormonal, and reversible male contraceptive hydrogel.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B2C
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Contraline Comparables
Compare Contraline with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Next Life Sciences | 88% | |
| VasDeBlock medical ApS | 79% | |
| Eppin Pharma Inc. | 76% |
For institutional investors. Book with your work email.
Contraline Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 2, 2026 | ||||
| Series A Extension | Nov 10, 2022 | ||||
| Series A | Oct 20, 2021 | ||||
| Early Funding | Mar 2, 2021 | ||||
| Grant | Nov 18, 2020 | ||||
Grant | Jan 24, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Contraline Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Male Contraceptive Initiative | Grant |
| RA Capital Management | Series B |
| GV | Series B, Series A Extension |
| Metaplanet Holdings | Series A, Series A Extension |
| Gaingels | Series A |
| Founders Fund | Series A, Seed |
| Invus Opportunities | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 17, 2026
Grew 15% QoQ, from 26 to 30 employees.
- Jun 22, 2026
Grew 25% QoQ, from 24 to 30 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 30, 2026
Contraline, Inc. is developing ADAM, a nonhormonal hydrogel designed to block sperm passage through the vas deferens and initially degrade on its own over two years.
For institutional investors. Book with your work email.
Contraline Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Contraline's valuation, stock price, and market status.
Is Contraline a public or private company?
Contraline is a private company.
What is the current stock price of Contraline?
Contraline is a private company, so its shares have no public market price. Caplight tracks Contraline's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Contraline worth (valuation)?
Contraline's valuation is estimated at $53.5M based on funding round data.
Can I buy Contraline stock?
Contraline shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Contraline's last funding round?
Contraline's most recent funding round was Series B on June 2, 2026.
Who are the main investors in Contraline?
Key investors in Contraline include RA Capital Management, GV, Founders Fund, BVF Partners L.P., FundRx.
Will Contraline IPO soon?
No public IPO plans have been announced for Contraline.
How can I track Contraline secondary market activity?
Caplight tracks bids, offers, and trades in Contraline's shares on secondary markets.